OBJECTIVE: Two monogenic @entity19 models of @entity2048 , stargazer and tottering, differ strikingly in their response to @entity3391 ( @entity3391 ) receptor blockade. We sought to evaluate the change in interictal relative gamma power as a reliable biomarker for this gene-linked antiepileptic drug (AED) response. METHODS: The effects of AEDs on absolute and relative (to the total) power of frequencies between 2 and 300 Hz were analyzed within the interictal electroencephalogram (EEG) and correlated with antiseizure efficacy in awake behaving stargazer, tottering, and wild-type (WT) littermate control @entity19 . RESULTS: At baseline, we found a significant absolute as well as relative augmentation of 16-41 Hz power in stargazer compared to both tottering and WT @entity19 . In stargazer, the @entity3391 receptor-antagonist @entity3390 (0.5 mg/kg) paradoxically exacerbates @entity2048 but normalizes the augmented beta/gamma band of power to WT levels, suggesting that the elevation in 16- to 41-Hz power is an @entity3391 receptor-mediated network property. In contrast, @entity17979 (200 mg/kg) and @entity973 (2.5 mg/kg) reduce @entity410 activity and increase relative power within the gamma range in both stargazer and tottering @entity19 . Intraperitoneal saline injection had no significant effect on either @entity410 frequency or relative gamma power. Along with results using @entity2049 and @entity29588 , there was a strong inverse relationship between relative change in @entity410 duration and change in peak relative gamma power (r(2) = 0.726). SIGNIFICANCE: In these two models of @entity2048 , drugs that reduce relative gamma power are associated with an increase in @entity410 , whereas drugs that augment relative gamma power reduce @entity410 . Therefore, drug-induced modulation of relative gamma power may serve as a biomarker for AED efficacy in @entity2048 . Given the relationship between gamma power and fast-spiking interneurons, these results also suggest that a drug's effect may in part be determined by its impact on specific inhibitory networks.

Shift in interictal relative gamma power as a novel biomarker for drug response in two @entity19 models of XXXX .

@entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity3391 :: ('D016202', 'Chemical') :: ['NMDA', 'N-methyl-d-aspartate'] @entity29588 :: ('MESH:C034161', 'Chemical') :: ['flupirtine'] @entity2048 :: ('MESH:D004832', 'Disease') :: ['absence seizures', 'childhood absence epilepsy', 'absence epilepsy'] @entity973 :: ('MESH:D015761', 'Chemical') :: ['4-aminopyridine'] @entity17979 :: ('MESH:D005013', 'Chemical') :: ['ethosuximide'] @entity3390 :: ('MESH:D016291', 'Chemical') :: ['MK-801'] @entity2049 :: ('MESH:D002220', 'Chemical') :: ['carbamazepine']
@entity2048 :: (MESH:D004832,Disease) :: ['absence epilepsy']
